About RNA Diagnostics
RNA Diagnostics is a Healthcare company based in Toronto (Canada) founded in 2010. Diagnostic assays for cancer detection via rRNA disruption are developed. RNA Diagnostics has raised $13.87 million across 5 funding rounds from investors including BDC and iGan Partners. The company has 49 employees. RNA Diagnostics offers products and services including Veridapt DX. Its focus areas include Life Sciences, Clinical Genomics, Sequencing Based and Precision Medicine. Its legal entity is Rna Diagnostics Inc.
Company details
RNA Diagnostics was established in 2010 in Toronto, Canada, within the biotechnology sector. Focus is placed on developing diagnostic assays to detect cancer, particularly breast cancer. The primary product, RNA Disruption Assay (RDA), is utilized to evaluate chemotherapy response by analyzing rRNA disruption levels in biopsy samples. Operations center on advancing these assays for clinical applications in oncology.
- Headquarters Toronto, Canada
- Employees 49
- SectorsHealthcare
- Website rnadiagnostics.com
- Social LinkedIn X
- Legal Name Rna Diagnostics Inc.
- Total Equity Funding$13.87M (USD)
in 5 rounds
- Latest Funding Round$34.71K (USD), Series A
Dec 2024
- InvestorsBDC
& 1 more
- Employee Count49
Products & Services of RNA Diagnostics
RNA Diagnostics offers a comprehensive portfolio of products and services, including Veridapt DX.
Measures early tumor response to cancer drugs for treatment guidance.
Funding Insights of RNA Diagnostics
RNA Diagnostics has successfully raised a total of $13.87M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $34.71 thousand completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13.87M
- Total Rounds 5
- Last Round Series A — $34,710
- First Round $800,000
(Sep 2015)
- Investors Count 2
All 5 funding rounds of RNA Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2024 | $34,710 | Series A | – | – | – |
| Nov 2024 | $35,763 | Series A | – | – | – |
| Sep 2021 | $8M | Series A | – | BDC | |
| Nov 2018 | $5M | Series A | – | iGan Partners | – |
| Sep 2015 | $800,000 | Angel Round | – | – | – |
2 investors in total: 2 institutional.
Investors in RNA Diagnostics
RNA Diagnostics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include BDC and iGan Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare-focused venture capital is provided by iGan Partners. | iganpartners.com | Toronto, Canada | ||
Commercial banking services for small and medium-sized enterprises are provided. | 1944 | bdc.ca | Montreal, Canada |
Investor details for RNA Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of RNA Diagnostics
2 people are tracked at RNA Diagnostics (2 in leadership); the tracked headcount is 49.
| Name | Role | Group |
|---|---|---|
Laura Pritzker | VP Operations and R&D | Leadership |
John Connolly | Chief Executive Officer | Leadership |
Complete people profiles for RNA Diagnostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of RNA Diagnostics
3 dated milestones of RNA Diagnostics across 14 years, from founding to its latest funding, stage changes and deals.
- Founded RNA Diagnostics is founded.
- Funding First funding round of $800K.
- Funding Latest funding round, Series A, of $35K.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rna Diagnostics
Complete news archive for RNA Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about RNA Diagnostics
RNA Diagnostics was founded in 2010 and raised its 1st funding round 5 years after it was founded.
RNA Diagnostics is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
RNA Diagnostics is a funded company, having raised a total of $13.87M across 5 funding rounds to date. The company's 1st funding round was a Angel Round of $800K, raised on Sep 2015.
RNA Diagnostics has 49 employees.
RNA Diagnostics was established in 2010 in Toronto, Canada, within the biotechnology sector. Focus is placed on developing diagnostic assays to detect cancer, particularly breast cancer. The primary product, RNA Disruption Assay (RDA), is utilized to evaluate chemotherapy response by analyzing rRNA disruption levels in biopsy samples. Operations center on advancing these assays for clinical applications in oncology.
RNA Diagnostics offers Veridapt DX.
RNA Diagnostics has 2 investors. Key investors include BDC, and iGan Partners.
RNA Diagnostics operates through Rna Diagnostics Inc..